Physician profile
Justin Kim
NPI 1629429139
$4,512.81
in general payments reported to CMS, 2019-2025
18 companies · $577 in 2025
The $577 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $289 · 2021: $891 · 2022: $575 · 2023: $510 · 2024: $646 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $822.66 | 2020-2025 | Eysuvis, Rocklatan, Tryptyr |
| Allergan, INC. | $516.25 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $448.13 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $430.23 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $381.54 | 2022-2025 | Infuse, Xiidra, Vyzulta |
| Kala Pharmaceuticals, INC. | $313.26 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $295.77 | 2019-2023 | |
| Oyster Point Pharma, INC. | $239.30 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $216.10 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $207.65 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $189.17 | 2019 | |
| Horizon Therapeutics Plc | $124.98 | 2021 | |
| Spark Therapeutics, INC. | $119.69 | 2019 | |
| Ivantis, INC | $100.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.50 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $24.67 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Harrow Eye, LLC | $18.09 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $15.82 | 2023 | Flarex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.